Predictive method for assessing the efficacy of tarlatamab

Clinical investigation of immunotherapeutic approaches for small cell lung cancer - Clinical investigation of immunotherapeutic approaches

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057875

Enrollment

Registered

2025-05-26

Start date

2025-06-16

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed as small cell lung cancer. Scheduled to undergo tarlatamab therapy. Provided informed consent.

Exclusion criteria

Exclusion criteria: Deemed inappropriate by the attending physician.

Design outcomes

Primary

Measure	Time frame
The correlation between peripheral T cell cytotoxicity and the therapeutic efficacy of tarlatamab.	—

Secondary

Measure	Time frame
The efficacy of tetracyclines in enhancing peripheral T cell cytotoxicity.	—

Countries

Japan

Contacts

Public ContactKota Iwahori

Osaka International Cancer Institute Department of Cancer Immunotherapy

kota.iwahori@oici.jp+81-6-6945-1181

Outcome results